Immune Therapeutics Signs LOI for China CAR-T Technology

Immune Therapeutics, a Florida biopharma, has signed a binding Letter of Intent to acquire a Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy developed in China. The company intends to acquire the technology from Super-T Cell Cancer Company, a newly formed corporation that is apparently associated with Immune's own Chief Science Officer, Fengpen Shan, PhD. Dr. Shan is Vice Director of the Institute of Immunology at China Medical University in Shenyang. Immune Therapeutics expects to develop the CAR-T technology for China use. more details.... Stock Symbol: (OTCQB: IMUN) Share this with colleagues: // //